Ex vivo Soft-laser treatment inhibits the synovial expression of vimentin and α-enolase, potential autoantigens in rheumatoid arthritis

Physical Therapy

Volumn 91, Issue 5, 2011, Pages 665-674

  Bálint, Géza ^a   Barabás, Klára ^b   Zeitler, Zsuzsanna ^c   Bakos, József ^c   Kékesi, Katalin A ^d   Pethes, Ákos ^e   Nagy, Erzsébet ^e   Lakatos, Tamás ^e   Bálint, Péter V ^b   Szekanecz, Zoltán ^f  

^a NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^b National Institute of Rheumatology and Physiotherapy   (Hungary)

^c Frederic Joliot Curie Natl Res I   (Hungary)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^e University of Debrecen Medical and Health Sciences Center ^*  (Hungary)

^f UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; ENOLASE; FERRITIN; HEAT SHOCK PROTEIN; KERATAN SULFATE; LUMICAN; OGN PROTEIN, HUMAN; PROTEOCHONDROITIN SULFATE; SIGNAL PEPTIDE; VIMENTIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; IN VITRO STUDY; LOW LEVEL LASER THERAPY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; POLYACRYLAMIDE GEL ELECTROPHORESIS; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; CASE-CONTROL STUDIES; CHONDROITIN SULFATE PROTEOGLYCANS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITINS; HEAT-SHOCK PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KERATAN SULFATE; LASER THERAPY, LOW-LEVEL; MASS SPECTROMETRY; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; SYNOVIAL MEMBRANE; VIMENTIN;

EID: 79960936183     PISSN: 00319023     EISSN: 15386724     Source Type: Journal    
DOI: 10.2522/ptj.20100065     Document Type: Article

References (79)

1. Huang Y-Y, Chen AC-H, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009; 7:358-383.
2. Goldman JA, Chiapella J, Casey H, et al. Laser therapy of rheumatoid arthritis. Lasers Surg Med. 1980;1:93-101.
3. Barabás K, Bakos J, Szabo LD, et al. In vitro effects of neodynium phosphate glass laser irradiation on the rheumatoid synovial membrane. Hungarian Rheumatology. 1987;28(suppl):58-62.
4. Basford JR. Low-energy laser therapy: controversies and new research findings. Lasers Surg Med. 1989;9:1-5.
5. Juhl C. Short-term beneficial effects of low level laser therapy for patients with rheumatoid arthritis. Aust J Physiother. 2006; 52:224.
6. Beckerman H, de Bie RA, Bouter LM, et al. The efficacy of laser therapy for musculoskeletal and skin disorders: a criteria-based meta-analysis of randomized clinical trials. Phys Ther. 1992;72:483-491.
7. Bliddal H, Hellesen C, Ditlevsen P, et al. Soft-laser therapy of rheumatoid arthritis. Scand J Rheumatol. 1987;16:225-228.
8. Christie A, Jamtvedt G, Dahm KT, et al. Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Phys Ther. 2007;87: 1697-1715.
9. Heussler JK, Hinchey G, Margiotta E, et al. A double blind randomised trial of low power laser treatment in rheumatoid arthritis. Ann Rheum Dis. 1993;52:703-706.
10. Aleksandrova O, Mikhailov VA, Maliavin AG. The effect of laser therapy on the quality of life of rheumatoid arthritis patients [in Russian]. Vopr Kurortol Fizioter Lech Fiz Kult. September-October 1999:35-37.
11. Hall J, Clarke AK, Elvins DM, Ring EF. Low level laser therapy is ineffective in the management of rheumatoid arthritic finger joints. Br J Rheumatol. 1994;33: 142-147.
12. Bouter LM. Insufficient scientific evidence for efficacy of widely used electrotherapy, laser therapy, and ultrasound treatment in physiotherapy [in Dutch]. Ned Tijdschr Geneeskd. 2000;144:502-505.
13. Brosseau L, Robinson V, Wells G, et al. Low level laser therapy (classes I, II and III) for treating rheumatoid arthritis. CochraneDatabase Syst Rev. 2005;4: CD002049.
14. Basford JR. Laser therapy: scientific basis and clinical role. Orthopedics. 1993;16: 541-547.
15. Yamaura M, Yao M, Yaroslavsky I, et al. Low level light effects on inflammatory cytokine production by rheumatoid arthritis synoviocytes. Lasers Surg Med. 2009; 41:282-290.
16. Aimbire F, Albertini R, Pacheco MT, et al. Low-level laser therapy induces dosedependent reduction of TNFalpha levels in acute inflammation. Photomed Laser Surg. 2006;24:33-37.
17. Klareskog L, Widhe M, Hermansson M, Rönnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol. 2008;20:300-305.
18. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142-R150.
19. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008;58: 3009-3019.
20. Barabás K, Bálint G, Gáspárdy G, et al. Kontrollierte klinische und experimentelle Untersuchungen mit Nd Phosphat- Glas-Laser bei Patienten mit Rheumatoid Arthritis bzw. ihre Wirkung auf die Synovial membrane. Z Physiother. 1989;41: 293-296.
21. Dasuri K, Antonovici M, Chen K, et al. The synovial proteome: analysis of fibroblastlikesynoviocytes. ArthritisResTher.2004;6: R161-R168.
22. Lea P, Keystone E, Mudumba S, et al. Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX: planar microarray diagnosis. Clin Rev Allergy Immunol. December 9, 2009 [Epub ahead of print].
23. Goeb V, Thomas-L'ottelier M, Daveau R, et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther.2009;11:R38.
24. Fanton GS, Dillinggam MF. The use of holmium laser in arthroscopic surgery. Seminars in Orthopaedics. 1992;7:108-116.
25. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
26. Esnouf A, Wright PA, Moore JC, Ahmed S. Depth of penetration of an 850nm wavelength low level laser in human skin. Acupunct Electrother Res. 2007;32:81-86.
27. Stolik S, Delgado JA, Pérez A, Anasagasti L. Measurement of the penetration depths of red and near infrared light in human "ex vivo" tissues. J Photochem Photobiol B. 2000;57:90-93.
28. Ettan DIGE System User Manual 18-1173-17, Edition AA. Budaörs, Hungary: Amersham Biosciences; 2002.
29. Rozanas CR, Loyland SM. Capabilities using 2-D DIGE in proteomics research: the new gold standard for 2-D gel electrophoresis. Methods Mol Biol. 2008;441: 1-18.
30. Qian WJ, Jacobs JM, Liu T, et al. Advances and challenges in liquid chromatographymass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics. 2006;5:1727-1744.
31. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163.
32. Soos L, Szekanecz Z, Szabo Z, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol. 2007;34:1658-1663.
33. Drynda S, Ringel B, Kekow M, et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti- TNFalpha therapy. Pathol Res Pract. 2004; 200:165-171.
34. Sinz A, Bantscheff M, Mikkat S, et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis. 2002;23: 3445-3456.
35. Tilleman K, Van Beneden K, Dhondt A, et al. Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics. 2005;5: 2247-2257.
36. Kim CW, Cho EH, Lee YJ, et al. Diseasespecific proteins from rheumatoid arthritis patients. J Korean Med Sci. 2006;21: 478-484.
37. Lorenz P, Ruschpler P, Koczan D, et al. From transcriptome to proteome: differentially expressed proteins identified in synovial tissue of patients suffering from rheumatoid arthritis and osteoarthritis by an initial screen with a panel of 791 antibodies. Proteomics. 2003;3:991-1002.
38. Matsuo K, Xiang Y, Nakamura H, et al. Identification of novel citrullinated auto antigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther. 2006;8:R175.
39. Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res. 2002;1: 495-499.
40. Lorenz P, Bantscheff M, Ibrahim SM, et al. Proteome analysis of diseased joints from mice suffering from collagen-induced arthritis. Clin Chem Lab Med. 2003;41: 1622-1632.
41. Szekanecz Z, Soos L, Szabo Z, et al. Anticitrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol. 2008;34:26-31.
42. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005;7: R1421-R1429.
43. Innala L, Kokkonen H, Eriksson C, et al. Antibodies against mutated citrullinated vimentin are a better predictor of diseaseactivity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol. 2008; 35:1002-1008.
44. Szodoray P, Szabo Z, Kapitany A, et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of diseaseoutcome in rheumatoid arthritis. Autoimmun Rev. 2010;9:140-143.
45. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolyticenzyme alpha-enolase in sera frompatients with early rheumatoid arthritis. Arthritis Rheum. 2002;46:1196-1201.
46. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994;21: 1027-1033.
47. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol.2003;5:59-63.
48. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentinto a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56:2503-2511.
49. Hayem G, Chazerain P, Combe B, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol. 1999;26:7-13.
50. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerningfuture radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum.2008;58:36-45.
51. Tabushi Y, Nakanishi T, Takeuchi T, et al. Detection of citrullinated proteins in synovial fluids derived from patientswith rheumatoid arthritis by proteomicsbasedanalysis. Ann Clin Biochem. 2008; 45:413-417.
52. Tilleman K, Van Steendam K, Cantaert T, et al. Synovial detection and autoantibody reactivity of processed citrullinated isoformsof vimentin in inflammatory arthritides. Rheumatology (Oxford). 2008;47: 597-604.
53. de Seny D, Fillet M, Meuwis MA, et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 2005;52:3801-3812.
54. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers. 2008;25:267-278.
55. Yildirim K, Karatay S, Melikoglu MA, et al. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci. 2004;34:423-426.
56. Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans. 2004;32:21-27.
57. Neumann E, Barnum SR, Tarner IH, et al. Local production of complement proteinsin rheumatoid arthritis synovium. ArthritisRheum. 2002;46:934-945.
58. Blochberger TC, Vergnes JP, Hempel J, Hassell JR. cDNA to chick lumican (corneal keratan sulfate proteoglycan) reveals homology to the small interstitial proteoglycan gene family and expression in muscle and intestine. J Biol Chem. 1992;267:347-352.
59. Funderburgh JL, Mitschler RR, Funderburgh ML, et al. Macrophage receptors for lumican: a corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci.1997;38:1159-1167.
60. Hedbom E, Heinegard D. Interaction of a 59-kDa connective tissue matrix protein with collagen I and collagen II. J Biol Chem. 1989;264:6898-6905.
61. Hedbom E, Heinegard D. Binding of fibromodulin and decorin to separate sites on fibrillar collagens. J Biol Chem. 1993;268: 27307-27312.
62. Svensson L, Aszo ́di A, Reinholt FP, et al. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem. 1999;274:9636-9647.
63. Gill MR, Oldberg A, Reinholt FP. Fibromodulin-null murine knee joints displayincreased incidences of osteoarthritis and alterations in tissue biochemistry. Osteoarthritis Cartilage. 2002;10: 751-757.
64. Kukita A, Bonewald L, Rosen D, et al. Osteoinductive factor inhibits formation of human osteoclast-like cells. Proc Natl Acad Sci U S A. 1990;87:3023-3026.
65. Hamajima S, Hiratsuka K, Kiyama- Kishikawa M, et al. Effect of low-level laser irradiation on osteoglycin gene expression in osteoblasts. Lasers Med Sci. 2003;18: 78-82.
66. Njemini R, Lambert M, Demanet C, Mets T. Elevated serum heat-shock protein 70 levels in patients with acute infection: use of an optimized enzyme-linked immunosorbentassay. Scand J Immunol. 2003;58:664-669.
67. Njemini R, Bautmans I, Lambert M, et al. Heat shock proteins and chemokine/ cytokine secretion profile in ageing and inflammation. Mech Ageing Dev. 2007; 128:450-454.
68. Schett G, Redlich K, Xu Q, et al. Enhancedexpression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1)activation in rheumatoid arthritis synovial tissue: differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and anti-inflammatory drugs. J Clin Invest. 1998;102:302-311.
69. Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol.2004;286:C739-C744.
70. Altmeyer A, Maki RG, Feldweg AM, et al. Tumor-specific cell surface expression of the KDEL-containing, endoplasmic reticular heat shock protein gp96. Int J Cancer.1996;69:340-349.
71. Liu B, Dai J, Zheng H, et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci U S A. 2003; 100:15824-15829.
72. Huang QQ, Sobkoviak R, Jockheck-Clark AR, et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J Immunol. 2009;182:4965-4973.
73. Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity. Isr Med Assoc J. 2008;10:83-84.
74. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007;1109:385-400.
75. Ota T, Katsuki I. Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis. J Rheumatol. 1998; 25:2315-2318.
76. Telfer JF, Brock JH. Expression of ferritin, transferrin receptor, and non-specific resistance associated macrophage proteins1 and 2 (Nramp1 and Nramp2) in the human rheumatoid synovium. Ann Rheum Dis. 2002;61:741-744.
77. Böhm BB, Aigner T, Blobel CP, et al. Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. Arthritis Rheum. 2001;44:2046-2054.
78. Robert-Pachot M, Desbos A, Moreira A, et al. A new target for autoantibodies in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:382-391.
79. Weiler T, Du Q, Krokhin O, et al. The identification and characterization of a novel protein, c19orf10, in the synovium. Arthritis Res Ther. 2007;9:R30.